Status:
UNKNOWN
The vPPG-detecting Software Guided Management of Cirrhotic Portal Hypertension
Lead Sponsor:
Changqing Yang
Conditions:
Portal Hypertension
Cirrhosis, Liver
Eligibility:
All Genders
18-75 years
Brief Summary
The aim of this study is to investigate the possibilities and effectiveness of managing cirrhotic portal hypertension using the non-invasive portal pressure gradient (PPG) detecting software. In this ...
Eligibility Criteria
Inclusion
- Inpatients (Shanghai Tongji Hospital) with cirrhosis, which is confirmed by the imaging tests (upper abdominal ultrasound/CT/MRI) or liver biopsy pathology.
Exclusion
- 1\. Portal vein embolism;
- 2\. Splenectomy;
- 3\. Hepatic encephalopathy;
- 4\. Hepatic space occupying lesions (such as hepatic cysts, hemangiomas, etc.) with diameter \> 3cm and local compression effect;
- 5\. Contraindications of enhanced CT test, such as iodine allergy, peripheral veins are too thin to inject contrast medium;
- 6\. Contraindications of upper GI endoscopy
Key Trial Info
Start Date :
March 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04786782
Start Date
March 3 2021
End Date
September 30 2023
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai, China, 200065